Article
Ophthalmology
Assaf Hilely, Adrian Au, K. Bailey Freund, Anat Loewenstein, Eric H. Souied, Dinah Zur, Riccardo Sacconi, Enrico Borrelli, Enrico Peiretti, Claudio Iovino, Yoshimi Sugiura, Abdallah A. Ellabban, Jordi Mones, Nadia K. Waheed, Sengul Ozdek, Duygu Yalinbas, Sarah Thiele, Luisa Salles de Moura Mendonca, Mee Yon Lee, Won Ki Lee, Pierre Turcotte, Vittorio Capuano, Meryem Filali Ansary, Usha Chakravarthy, Albrecht Lommatzsch, Frederic Gunnemann, Daniel Pauleikhoff, Michael S. Ip, Giuseppe Querques, Frank G. Holz, Richard F. Spaide, SriniVas Sadda, David Sarraf
Summary: This study evaluated the patterns of subretinal fluid in eyes with non-neovascular AMD and found that SRF may be a result of RPE decompensation and RPE pump failure.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Virginia Mares, Ursula Margarethe Schmidt-Erfurth, Oliver Leingang, Philipp Fuchs, Marcio B. Nehemy, Hrvoje Bogunovic, Daniel Barthelmes, Gregor S. Reiter
Summary: This study uses artificial intelligence technology to predict treatment requirements, visual acuity, and morphological outcomes in patients with neovascular age-related macular degeneration. By processing spectral-domain optical coherence tomography data and using a deep learning algorithm for segmentation, future treatment requirements and morphological outcomes can be accurately predicted.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Medicine, General & Internal
Alper Bilgic, Laurent Kodjikian, Francesc March de Ribot, Vaishali Vasavada, Jesus H. Gonzalez-Cortes, Amro Abukashabah, Aditya Sudhalkar, Thibaud Mathis
Summary: The study aimed to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration in real-world settings. Results showed good anatomical and functional responses to the treatment, with two significant untoward events noted.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Prem Patel, Veeral Sheth
Summary: AMD is a common cause of vision loss, with two main types, neovascular and non-neovascular, treated primarily through inhibition of VEGF. Discrepancies between clinical trial results and real-world outcomes exist, indicating the potential for new treatments to improve therapeutic efficacy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biology
Oluchukwu Onwuka, Jackson L. Saddemi, Fatma Sema Akkan Aydogmus, Claudia C. Lasalle, David J. Ramsey
Summary: This study examined the relationship between the interval of monitoring the at-risk eyes of patients with unilateral neovascular age-related macular degeneration (nAMD) and the severity of the disease at diagnosis. The study compared the visual acuity and central macular thickness of patients who were actively receiving anti-VEGF treatment at the time of second eye diagnosis with patients who had discontinued treatment in their first eye. The results showed that the at-risk eyes of patients who had stopped treatment prior to fellow eye conversion were monitored less frequently than those who continued treatment. However, the visual acuity and central macular thickness were similar at the time of fellow eye diagnosis for both groups.
Article
Nutrition & Dietetics
Harshil Dharamdasani Detaram, Gerald Liew, Joshua R. Lewis, Nicola P. Bondonno, Catherine P. Bondonno, Kim Van Vu, George Burlutsky, Jonathan M. Hodgson, Paul Mitchell, Bamini Gopinath
Summary: The study found that dietary intake of flavonoids is associated with treatment outcomes in nAMD patients. Patients with higher intake of specific flavonoids may have better long-term treatment outcomes after receiving anti-VEGF therapy.
EUROPEAN JOURNAL OF NUTRITION
(2021)
Article
Ophthalmology
Tyler E. Greenlee, Victoria Y. Wang, Hannah Kang, Marc E. Ohlhausen, Andrew X. Chen, Grant L. Hom, Thais F. Conti, Isaac Briskin, Amy S. Babiuch, Rishi P. Singh
Summary: The study found that patients with neovascular age-related macular degeneration who experience treatment lapses may exhibit significant increase in central subfield thickness and loss in visual acuity. Although macular thickness normalizes on resumption of treatment, their decline in visual acuity does not recover within 12 months of follow-up.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2021)
Article
Medicine, General & Internal
Joanna Ladkowska, Maciej Gawecki, Marek Szolkiewicz
Summary: This study found that the presence of cardiovascular risk factors, especially hypertension, in patients with neovascular age-related macular degeneration negatively impacts visual acuity outcomes following anti-VEGF therapy. Patients with higher total cholesterol levels showed better visual improvement, but this did not significantly affect the percentage of responders.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Yun Zhang, Sheng Gao, Xun Li, Xi Huang, Yi Zhang, Tiancong Chang, Zhaolun Cai, Meixia Zhang
Summary: The study evaluated the efficacy and safety of anti-VEGF monotherapy in nAMD patients and concluded that brolucizumab, aflibercept, and ranibizumab are the ideal treatment regimens.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Filomena Palmieri, Saad Younis, Walid Raslan, Lorenzo Fabozzi
Summary: This study reports the clinical and multimodal imaging findings of patients with neovascular age-related macular degeneration who developed bacillary layer detachment. The research was conducted at the Western Eye Hospital in London, UK. The results show that bacillary layer detachment can be detected in patients with neovascular age-related macular degeneration, which is not commonly described in the literature for this disease.
Review
Ophthalmology
Vincent Daien, Robert P. Finger, James S. Talks, Paul Mitchell, Tien Y. Wong, Taiji Sakamoto, Bora M. Eldem, Jean-Francois Korobelnik
Summary: The study aimed to evaluate the contribution of real-world evidence in changing anti-VEGF therapy treatment practices for nAMD. The findings suggest that T&E regimens optimize visual outcomes while reducing burden on patients, clinics and physicians, making it the most likely to adequately balance clinical outcomes and treatment burden for nAMD patients.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Tyler Hyungtaek Rim, Aaron Y. Lee, Daniel S. Ting, Kelvin Teo, Bjorn Kaijun Betzler, Zhen Ling Teo, Tea Keun Yoo, Geunyoung Lee, Youngnam Kim, Andrew C. Lin, Seong Eun Kim, Yih Chung Tham, Sung Soo Kim, Ching-Yu Cheng, Tien Yin Wong, Chui Ming Gemmy Cheung
Summary: The study evaluated the generalization ability of a DL model trained on Korean data to an American data set, and confirmed its accuracy through expert grading.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Medicine, General & Internal
Soo Chang Cho, Kyu Hyung Park, Sang Jun Park, Kwangsic Joo, Se Joon Woo
Summary: This study investigated the discontinuation rate and retreatment in the real-world setting of anti-VEGF injections in tnAMD and PCV. The results showed that 66% of eyes discontinued treatment with a median time of 1.5 years after the initial injection.
FRONTIERS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Ling Yeung, Yi-Ting Hsieh, Chang-Hao Yang, Lee-Jen Chen, Shih-Jen Chen, Cheng-Kuo Cheng, Shwu-Jiuan Sheu, Ching-Yao Tsai, Tsung-Tien Wu, Wei-Chi Wu, San-Ni Chen
Summary: The article provides recommendations on diagnosis, treatment, and follow-up strategies for neovascular age-related macular degeneration, focusing on comprehensive ophthalmologic examination, anti-VEGF therapy, treatment regimen selection and adjustment, and patient education.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Maya Kishi, Akiko Miki, Aya Kamimura, Mina Okuda, Wataru Matsumiya, Hisanori Imai, Sentaro Kusuhara, Makoto Nakamura
Summary: This retrospective study evaluated the functional and anatomical effects of switching to faricimab for neovascular age-related macular degeneration (nAMD) patients who were refractory to intravitreal aflibercept. The results showed that after switching, the patients experienced a significant decrease in central retinal thickness (CRT), an extended injection interval, and a decrease in the presence of intraretinal fluid and subretinal fluid. However, best-corrected visual acuity (BCVA) and central choroidal thickness (CCT) did not change significantly. The study suggests that switching to faricimab could be an additional treatment option for nAMD patients who are refractory to aflibercept.
JOURNAL OF CLINICAL MEDICINE
(2023)